Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses MLYS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MLYS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jon Congleton | $636,500 | $0 | $0 | $4,435,626 | $472,601 | $0 | $0 | $5,544,727 |
| President and Chief Executive Officer | ||||||||
| David Rodman | 533,000 | 25,000 | 0 | 1,322,906 | 323,798 | 0 | 0 | 2,204,704 |
| Chief Medical Officer | ||||||||
| Adam Levy | 532,000 | 25,000 | 0 | 1,322,906 | 323,190 | 0 | 0 | 2,203,096 |
| Chief Financial Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jon Congleton | $5,544,727 | $5,420,868 | — | +123,859 |
| David Rodman | 2,204,704 | 2,877,749 | — | −673,045 |
| Adam Levy | 2,203,096 | 2,849,200 | — | −646,104 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Adam Levy | RSU | 6,524 | — | $236,756 |
| Adam Levy | Option | 85,968 | 14.25 | — |
| Adam Levy | Option | 4,373 | 15.44 | — |
| Jon Congleton | RSU | 95,881 | — | 3,479,521 |
| Adam Levy | RSU | 6,526 | — | 236,829 |
| Jon Congleton | Option | 72,931 | 16 | — |
| Jon Congleton | Option | 31,188 | 15.44 | — |
| Jon Congleton | Option | 230,209 | 14.25 | — |
| Jon Congleton | Option | 451,251 | 10.2 | — |
| Adam Levy | Option | 19,410 | 16 | — |
| Adam Levy | Option | 129,319 | 10.2 | — |
| David Rodman | Option | 30,388 | 16 | — |
| David Rodman | Option | 6,250 | 15.44 | — |
| David Rodman | Option | 108,334 | 14.25 | — |
| David Rodman | Option | 134,584 | 10.2 | — |
The company's compensation program is designed to provide appropriate incentives to executives to achieve defined annual corporate goals and to reward individual achievement, while equity-based incentive awards are designed to align the interests of the company and its stockholders with those of its employees.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Glenn P. SblendorioIndependent · Board Chair · Compensation · Audit | $84,267 | — | $247,043 | — | — | $331,310 |
| Daphne KarydasIndependent · Audit (Chair) | 60,000 | — | 247,043 | — | — | 307,043 |
| Alexander Gold, M.DIndependent · Compensation · Nominating and Corporate Governance | 58,233 | — | 247,043 | — | — | 305,276 |
| Derek DiRoccoIndependent | 57,500 | — | 247,043 | — | — | 304,543 |
| Derek DiRocco, Ph.DIndependent · Compensation · Audit | 57,500 | — | 247,043 | — | — | 304,543 |
| Srinivas Akkaraju, M.D., Ph.DIndependent · Compensation · Nominating and Corporate Governance | 45,884 | — | 247,043 | — | — | 292,927 |
| Brian Taylor Slingsby, M.D., Ph.D., M.P.HIndependent · Compensation · Nominating and Corporate Governance (Chair) | 0 | — | 247,043 | — | — | 247,043 |
| Jon CongletonEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $363,384 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $363,384 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Mineralys Therapeutics | 2025 | Jon Congleton | $636,500 | $0 | $4,435,626 | $472,601 | $5,544,727 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jon Congleton | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Executive Compensation”. As printed: 5,544,727. Filing ↗machine: r2 · c48 · span 235758–235767 |
| 2 | Section 01, David Rodman | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Executive Compensation”. As printed: 2,204,704. Filing ↗machine: r6 · c48 · span 246847–246856 |
| 3 | Section 01, Adam Levy | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Executive Compensation”. As printed: 2,203,096. Filing ↗machine: r4 · c48 · span 241311–241320 |
| 4 | Section 08, Glenn P. Sblendorio | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 331,310. Filing ↗ |
| 5 | Section 08, Daphne Karydas | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 307,043. Filing ↗ |
| 6 | Section 08, Alexander Gold, M.D | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 305,276. Filing ↗ |
| 7 | Section 08, Derek DiRocco | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 304,543. Filing ↗ |
| 8 | Section 08, Derek DiRocco, Ph.D | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 304,543. Filing ↗ |
| 9 | Section 08, Srinivas Akkaraju, M.D., Ph.D | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 292,927. Filing ↗ |
| 10 | Section 08, Brian Taylor Slingsby, M.D., Ph.D., M.P.H | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 247,043. Filing ↗ |
| 11 | Section 08, Jon Congleton | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | computed | Cash 363,384 + equity 0 + all other 0 = 363,384, summed across the director compensation table rows.machine: formula: Σ = 363,384 |
| 14 | Mineralys Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-08 | 0001933414-26-000069 | CEO total compensation as printed in Mineralys Therapeutics's own proxy. As printed: 5,544,727. Filing ↗machine: r2 · c48 · span 235758–235767 |